What was the overall market valuation of the US hydronephrosis market in 2024?

The overall market valuation was $350.7 Million in 2024. Read More

What is the projected market valuation for the US hydronephrosis market by 2035?

The projected market valuation for 2035 is $564.95 Million. Read More

What is the expected CAGR for the US hydronephrosis market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period 2025 - 2035 is 4.43%. Read More

Which companies are considered key players in the US hydronephrosis market?

Key players include Fresenius Medical Care, Baxter International, Medtronic, Boston Scientific, Johnson & Johnson, Stryker Corporation, Terumo Corporation, and Cook Medical. Read More

What are the primary diagnosis methods used in the US hydronephrosis market?

Primary diagnosis methods include Ultrasound ($70.0 - $110.0 Million), CT Scan ($90.0 - $140.0 Million), MRI ($60.0 - $90.0 Million), X-ray ($50.0 - $80.0 Million), and Urodynamics ($80.7 - $144.95 Million). Read More

What treatment methods are utilized in the US hydronephrosis market?

Treatment methods include Medication ($70.0 - $110.0 Million), Surgery ($120.0 - $180.0 Million), Catheterization ($50.0 - $80.0 Million), Dialysis ($40.0 - $70.0 Million), and Monitoring ($70.7 - $124.95 Million). Read More

What are the leading causes of hydronephrosis in the US market?

Leading causes include Kidney Stones ($105.21 - $168.15 Million), Infections ($87.78 - $138.85 Million), Tumors ($70.14 - $109.43 Million), Congenital Abnormalities ($35.07 - $56.495 Million), and Pregnancy ($52.6 - $82.0 Million). Read More

Which end users are primarily involved in the US hydronephrosis market?

Primary end users include Hospitals ($140.0 - $225.0 Million), Clinics ($70.0 - $110.0 Million), Diagnostic Centers ($50.0 - $85.0 Million), Home Care ($40.0 - $70.0 Million), and Research Institutes ($50.7 - $74.95 Million). Read More

How does the market for hydronephrosis treatment appear to be evolving?

The market appears to be evolving positively, with a projected increase in valuation from $350.7 Million in 2024 to $564.95 Million by 2035. Read More

What role do key players like Medtronic and Boston Scientific play in the market?

Key players like Medtronic and Boston Scientific likely contribute to innovation and market growth through advanced treatment technologies and comprehensive healthcare solutions. Read More

US Hydronephrosis Market

ID: MRFR/Pharma/16779-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Hydronephrosis Market Research Report: By Diagnosis Method (Ultrasound, CT Scan, MRI, X-ray, Urodynamics), By Treatment Method (Medication, Surgery, Catheterization, Dialysis, Monitoring), By Cause of Condition (Congenital Abnormalities, Kidney Stones, Tumors, Pregnancy, Infections) and By End User (Hospitals, Clinics, Diagnostic Centers, Home Care, Research Institutes) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Diagnosis Method (USD Million)
  1. 4.1.1 Ultrasound
  2. 4.1.2 CT Scan
  3. 4.1.3 MRI
  4. 4.1.4 X-ray
  5. 4.1.5 Urodynamics
2. 4.2 Life Sciences, BY Treatment Method (USD Million)
  1. 4.2.1 Medication
  2. 4.2.2 Surgery
  3. 4.2.3 Catheterization
  4. 4.2.4 Dialysis
  5. 4.2.5 Monitoring
3. 4.3 Life Sciences, BY Cause of Condition (USD Million)
  1. 4.3.1 Congenital Abnormalities
  2. 4.3.2 Kidney Stones
  3. 4.3.3 Tumors
  4. 4.3.4 Pregnancy
  5. 4.3.5 Infections
4. 4.4 Life Sciences, BY End User (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Clinics
  3. 4.4.3 Diagnostic Centers
  4. 4.4.4 Home Care
  5. 4.4.5 Research Institutes
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Fresenius Medical Care (DE)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Baxter International (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Medtronic (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Boston Scientific (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Johnson & Johnson (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Stryker Corporation (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Terumo Corporation (JP)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Cook Medical (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY DIAGNOSIS METHOD
3. 6.3 US MARKET ANALYSIS BY TREATMENT METHOD
4. 6.4 US MARKET ANALYSIS BY CAUSE OF CONDITION
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY DIAGNOSIS METHOD, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
14. 6.14 LIFE SCIENCES, BY TREATMENT METHOD, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY TREATMENT METHOD, 2024 TO 2035 (USD Million)
16. 6.16 LIFE SCIENCES, BY CAUSE OF CONDITION, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY CAUSE OF CONDITION, 2024 TO 2035 (USD Million)
18. 6.18 LIFE SCIENCES, BY END USER, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT METHOD, 2025-2035 (USD Million)
  3. 7.2.3 BY CAUSE OF CONDITION, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Life Sciences Market Segmentation

Life Sciences By Diagnosis Method (USD Million, 2025-2035)

Ultrasound
CT Scan
MRI
X-ray
Urodynamics

Life Sciences By Treatment Method (USD Million, 2025-2035)

Medication
Surgery
Catheterization
Dialysis
Monitoring

Life Sciences By Cause of Condition (USD Million, 2025-2035)

Congenital Abnormalities
Kidney Stones
Tumors
Pregnancy
Infections

Life Sciences By End User (USD Million, 2025-2035)

Hospitals
Clinics
Diagnostic Centers
Home Care
Research Institutes

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”